AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02779335 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enteral Formula
Description: pediatric subjects will be fed a standard pediatric enteral formula tube feeding
Study NCT01063920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-NS001
Description: 1200 mg b.i.d. p.o. for 12 weeks
Study NCT02677363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
Study NCT04114240 — intervention group
Intervention type: DRUG
Intervention: Xybilun
Description: Erectil dysfunction, Viagra generic (sildénafil)
Study NCT03936413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bay Labs EchoGPS Echcoardiogram
Description: An echocardiogram will be performed in this arm using the Bay Labs EchoGPS. The Bay Labs EchoGPS system is an ultrasound system which uses the techniques of computer vision to analyze echocardiography images in real time. It then provides feedback to the user to optimize the images, and once they meet a specific level of quality it automatically records the images.
Study NCT03936413 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Native Terason Echocardiogram
Description: An echocardiogram will be performed in this arm using a native Terason echocardiography system. This system will not have any artificial intelligence assistance in image optimization or selection.
Study NCT05096676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin: Including placebo
Description: Individual received age-dependent dosing of oxytocin and placebo. Participants aged 13-18 years received a dose of 24 IU (3 puffs to each nostril), and younger participants (aged 12 years) received 16 IU.
Study NCT02161601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cricoid Pressure
Description: Correct Cricoid pressure applied against the cricoid cartilage, Incorrect Cricoid pressure applied against the thyroid cartilage and trachea
Study NCT03903679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask airway
Description: Patients will be maintained with laryngeal mask airway during the septal surgery.
Study NCT03903679 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Endotracheal tube
Description: Patients will be maintained with endotracheal tube during the septal surgery.
Study NCT01512745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT01512745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT01474447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grinberg Method
Description: The GM is a methodology of attention that teaches through expanding and focusing body attention to create a change and an improvement in pain and in quality of life. The method focuses on the way in which we experience pain, and offers an approach that trains people to use their attention and will in order to turn an unwanted experience that causes suffering, into a controlled experience in which they can take responsibility on the way they react to an existing pain. The method uses attention in order to learn the fixed ways in which we respond to pain in our body: where we focus our attention, what is the level of tension in our muscles, how we breathe and relax and more. It gives simple and effective tools to control all these, in order to create optimal conditions in the body to utilize its natural potential to recover and recuperate
Study NCT04299477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal treatment
Description: supra- and subgingival scaling, and root planning
Study NCT04095572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravesical instillation with HA-CS
Description: intravesical instillation with HA-CS (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Lodi, Italy)
Study NCT01063920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn®
Description: 500 mg b.i.d. p.o. for 12 weeks
Study NCT04255732 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: extent of retinal area viewing Optos, Daytona, Optos PLC, Dunfermline, UK
Description: Comparison of the extent of retinal periphery view between two wide field imaging devices.
Study NCT04255732 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: extent of retinal area viewing Clarus, 500 Carl Zeiss, Meditec AG, Jena, Germany
Description: Comparison of the extent of retinal periphery view between two wide field imaging devices.
Study NCT01942499 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Community-based exercise program
Study NCT04095572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravesical instillation of sterile purified water
Description: intravesical instillation of sterile purified water (packed and labelled according to Good Manufacturing Practice at IBSA Farmaceutici Italia Srl in Lodi, Italy to provide adequate blinding)
Study NCT00437021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (subcutaneous)
Description: 0.9 percent (weight/volume) sodium chloride injection, United States Pharmacopeia \[Sterile Saline Placebo (SSP)\].
Study NCT00437021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (scarification)
Description: Physiologic normal saline for injection.
Study NCT00437021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (scarification)
Description: Physiologic normal saline for injection.
Study NCT00437021 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dryvax®
Description: Dryvax® Vaccinia Vaccine (\~10\^5 \[plaque forming units (pfu)/dose\] given via scarification, titer 10\^8 pfu per mL after reconstitution).
Study NCT00437021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dryvax®
Description: Dryvax® Vaccinia Vaccine (\~10\^5 \[plaque forming units (pfu)/dose\] given via scarification, titer 10\^8 pfu per mL after reconstitution).
Study NCT00437021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE®
Description: IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route at titer 1X10\^8 Tissue Culture Infections Dose50 per 0.5 mL dose.
Study NCT01719237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacine and Chloroprocaine mixture
Description: Chloroprocaine is added to Ropivacaine
Study NCT01719237 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine only
Description: Ropivacaine diluted with normal saline instead of chloroprocaine
Study NCT01536145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability
Study NCT03999905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling training
Description: Online training using Moodle.
Study NCT03160300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music with Binaural Beats
Description: Relaxing music with embedded binaural beats at a frequency of 5 Hz
Study NCT03160300 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Music
Description: Relaxing music without a binaural beat component
Study NCT00038441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTI-015
Description: DTI-015 injected through a catheter into center of brain tumor.
Study NCT01613027 — intervention group
Intervention type: BIOLOGICAL
Intervention: Rituximab
Description: Rituximab administered according to prescribing information and normal clinical practice.
Study NCT02348853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Weight for Living (HWL)
Study NCT02348853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Current Best Practice (CBP)
Study NCT03551808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: using of Ketorolac Tromethamine Eye Drop
Description: using of Ketorolac Tromethamine Eye Drop one day before the surgery in each 8 hours and continue it for 4 weeks after the surgery
Study NCT02231437 — intervention group
Intervention type: DRUG
Intervention: Berodual®
Study NCT00672958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated immediate-release tablets.
Study NCT00672958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo-matching capsules.
Study NCT04422639 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRS/SRT
Description: Comparing pre-operative SRS/SRT to post-operative SRS/SRT
Study NCT04422639 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SRS/SRT
Description: Comparing pre-operative SRS/SRT to post-operative SRS/SRT
Study NCT01348776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hair2Go (Mē)
Description: Treatment with Hair2Go Device 7 times every week with maintenance treatments once a month for 3 months
Study NCT02240719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT02240719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV
Study NCT01108510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COBI
Description: Cobicistat (COBI) 150 mg tablet administered orally once daily
Study NCT01108510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: Ritonavir (RTV) 100 mg tablet administered orally once daily
Study NCT01108510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Atazanavir (ATV) 300 mg capsule administered orally once daily
Study NCT01108510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV
Description: Atazanavir (ATV) 300 mg capsule administered orally once daily
Study NCT01108510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
Study NCT01108510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
Study NCT01108510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COBI placebo
Description: Placebo to match COBI administered orally once daily
Study NCT01108510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV placebo
Description: Placebo to match RTV administered orally once daily
Study NCT03568721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: prescription of ibuprofen 400 mg
Study NCT03568721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: prescription of acetaminophen 500 mg
Study NCT03568721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: prescription of one tablet of chewing gum
Study NCT02526056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapists
Description: This study is a usability design with qualitative and quantitative aspects. The therapeutic relevance and design features will be explored.
Study NCT02526056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elderly people
Description: In one part, with patients, physical strain and designs facets will be investigated. During their game playing process, different measurements will be done. They will be asked about their opinions about the game.
Study NCT04924972 — intervention group
Intervention type: PROCEDURE
Intervention: Blepharoplasty
Description: 90 patients undergoing bilateral upper eyelid blepharoplasty are randomly assigned to a suturing technique (running cutaneous or subcuticular Nylon (6-0 Prolene) sutures). Steri-strips will be used until suture removal 7 days after blepharoplasty for patient blinding.
Study NCT05246319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: preoperative imaging
Description: evaluation of preoperative imaging (versus nodes observed on pathology)
Study NCT04622137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping therapy
Description: The investigators used kinesiotaping strips in formations such as the Y, I, X, fan, web, and donut formations ove fractured clavicula.
Study NCT03118544 — intervention group
Intervention type: DEVICE
Intervention: DyeVert System
Description: The DyeVert System (Osprey Medical, Inc) consists of a Contrast Monitoring Wireless Display (CMW) and the DyeVert Plus Disposable Kit which is inclusive of a disposable single-use sterile Smart Syringe and DyeVert Plus Module.
Study NCT04521517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning
Description: a pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning
Study NCT01440127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pills will be taken for one week prior to the scheduled surgery or biopsy procedure.
Study NCT03971812 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: A blood sample of two 10 mL ethylenediaminetetraacetic (EDTA) tubes will be taken at the time of the visit. This sample will be centrifuged for isolation of peripheral blood mononuclear cells (PBMC).
Study NCT04683523 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Resistance training using dumbbells and therabands
Study NCT04683523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Resistance training using dumbbells and therabands
Study NCT01018641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SA3Ag vaccine
Description: In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive 0.5 mL IM of the same dose level he/she received in stage 1.
Study NCT01018641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
Study NCT01018641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonization swab samples
Description: Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
Study NCT01018641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SA3Ag followed by Placebo
Description: In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive one injection of 0.5 mL IM of the placebo.
Study NCT01018641 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In both stage 1 and stage 2, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl for a total of 2 injections throughout the study.
Study NCT01018641 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood draw
Description: Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
Study NCT01018641 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colonization swab samples
Description: Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
Study NCT01018641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SA3Ag with no booster in stage 2
Description: In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive no vaccine.
Study NCT01018641 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with no booster in stage 2
Description: In stage 1, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl.~In stage 2 the subject will receive no vaccine.
Study NCT00592046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-101 (Darinaparsin)
Description: ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.
Study NCT02340702 — intervention group
Intervention type: OTHER
Intervention: COPD
Description: COPD as diagnosed clinically or based on pulmonary function test showing post-bronchodilator forced expiratory volume in one second to forced vital capacity ratio of \<0.7.
Study NCT03289598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A rehabilitation process involving collaborative goal setting with a case manager about managing own food and meals
Description: The intervention consists of two parts:~1. Education of the health care staff with three day's education focusing of aspects of food, meals and nutrition to old people.~2. The individual participants in the intervention group will be participating in a rehabilitation process involving collaborative goal setting with a case manager. All the case managers have a background as registered dietician and will before start of the intervention be trained in managing a rehabilitation process with focus on meals and food. The training will consist of three days of education in, respectively, areas in relation to rehabilitation and the role as a care manager. Specific topics include; assessment of functional abilities in relation to meals and food; goal setting by means of GAS (Goal Attainment Scaling), ethical considerations and communication.
Study NCT02062710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo
Description: diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg; placebo.
Study NCT02062710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan
Description: diphenhydramine 25 mg and phenylephrine 10 mg; placebo; dextromethorphan 30 mg.
Study NCT02062710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo
Description: dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg; placebo
Study NCT02062710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa
Description: dextromethorphan 30 mg; placebo; diphenhydramine 25 mg and phenylephrine 10 mg
Study NCT02062710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan
Description: placebo; diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg
Study NCT02062710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa
Description: placebo; dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg
Study NCT02664467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips EnergyUp EnergyLight HF3419/01
Description: Bright light therapy (10'000 lux) for 60 minutes after wake-up
Study NCT02664467 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Philips EnergyUp EnergyLight HF3419/01
Description: Placebo dim light (500 lux) for 60 minutes after wake-up
Study NCT03622398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with HXLPE liner
Description: Replacing arthritic knee with a metal device, and using a highly cross-linked polyethylene(HXLPE) liner in between metallic surfaces.
Study NCT03622398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty with conventional polyethylene liner
Description: Replacing arthritic knee with a metal device, and using a conventional polyethylene liner in between metallic surfaces.
Study NCT00748189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorambucil, tablets
Description: 2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
Study NCT00748189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorambucil, tablets
Description: 2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
Study NCT00748189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab (GSK1841157) infusion
Description: iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
Study NCT02585817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote CIED Management
Description: Information Technology